Closed Fracture of Hip Clinical Trial
Official title:
Tranexamic Acid in Hip Fracture Patients
This is a randomized controlled trial comparing the use of tranexamic acid to placebo in patients admitted to hospital with a hip fracture.
1. transfusion of allogeneic RBC's is not free of adverse events and has been associated
with an increased risk of postoperative infection
2. Tranexamic acid in trauma patients has been shown to reduce 30-day mortality. Hospital
trauma protocol includes tranexamic acid in patients with major bleeding.
3. Tranexamic acid in orthopedic elective joint reconstruction surgery has been shown to
substantially decrease bleeding in knee and hip arthroplasty.
4. in hip fracture surgery, transexamic acid reduces erythrocyte transfusion rate but may
promote a hypercoagulable state.
5. Tranexamic acid is an antifibrinolytic drug that inhibits plasminogen from turning into
plasmin thereby inhibiting clot breakdown.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02621255 -
Effect of Anesthesia in Fracture Healing
|
Phase 4 | |
| Completed |
NCT01473082 -
Proximal Femoral Nail Antirotation (PFNA) Versus PFNA Augmentation
|
Phase 4 |